EXCEL Trial Extended Long-term Results and Key Clinical Substudies Gregg W. Stone, MD

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, NY and the Cardiovascular Research Foundation





General Disclosure Statement of Financial Interest

Speaker honoraria from Cook; Consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Miracor, Neovasc, Abiomed, Ancora, Vectorious; Equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix

Disclosure Statement of Financial Interest with Stent Manufacturers


None








EXCEL: Study Design




Follow-up: 1 month, 6 months, 1 year, annually through 5 years Primary endpoint: <u>Death, MI or stroke</u> measured at median 3-yr FU, min 2-yr FU



SYNTAX Score



EXCEL Primary Endpoint All-cause Death, Stroke or MI at 5 Years



EXCEL Analysis of 10 pre-specified subgroups All-cause Death, Stroke or MI at 5 Years

Subgroup	PCI N=948	CABG N=957	OR [95% CI]	OR [95% CI]	P _{int}	Subgroup	PCI N=948	CABG N=957	OR [95% CI]	OR [95% CI]	P _{int}
All patients	22.0% (203/948)	19.2% (176/957)	1.19 [0.95, 1.50]			All patients	22.0% (203/948)	19.2% (176/957)	1.19 [0.95, 1.50]	- -	
Age (median cutoff)						Left ventricular eje	ction fraction				
- ≥67 years	27.2% (123/466)	21.8% (98/472)	1.39 [1.02, 1.89]			- ≥50%	20.6% (158/782)	18.7% (144/796)	1.14 [0.88, 1.46]		
- <67 years	16.9% (80/482)	16.6% (78/485)	1.00 [0. 71, 1.40]		0.95	- <50%	31.5% (33/111)	24.2% (26/115)	1.35 [0.73, 2.49]		0.61
						Non loft main diag	and coronary artarias		a+)		
<u>Sex</u>							ased coronary arteries				
- Male	20.6% (145/722)	18.7% (134/742)	1.12 [0.86, 1.46]		0.42	- 0	20.7% (33/163)	14.3% (23/167)	1.55 [0.86, 2.78]		
- Female	26.3% (58/226)	21.1% (42/215)	1.39 [0.88, 2.20]			- 1	21.2% (60/292)	21.9% (61/292)	0.94 [0.62, 1.40]		0.29
						- 2	25.0% (79/325)	17.8% (50/295)	1.58 [1.06, 2.36]		
<u>Diabetes mellitus, m</u>	edically treated					- 3	19.2% (31/162)	20.7% (37/182)	0.93 [0.54, 1.59]		
- Yes	29.0% (72/256)	25.5% (62/249)	1.24 [0.83, 1.86]		0.04	Left main bifurcation	on or trifurcation sten	osis ≥50% (core lab a	assessment)		
- No	19.4% (131/692)	16.9% (114/707)	1.17 [0.89, 1.55]		0.81	- Yes	22.7% (171/771)	19.0% (136/741)	1.24 [0.96, 1.60]		
						- No	19.2% (32/171)	18.9% (35/195)	1.05 [0.62, 1.79]	<mark>_</mark>	0.58
<u>Chronic kidney disea</u>	<u>se</u>					Syntax score (site r	enorted)				
- eGFR ≤60 ml/min	34.0% (54/164)	27.6% (37/144)	1.44 [0.86, 2.39]		0.41			10 70/ /100 /500)	1 21 [0 00 1 02]		
- eGFR >60 ml/min	19.5% (147/770)	17.6% (135/791)	1.13 [0.87, 1.47]		0.41	- ≤22	21.9% (119/560)	18.7% (106/588)	1.21 [0.90, 1.62]		0.88
						- 23 - 32	22.2% (84/386)	20.0% (70/366)	1.16 [0.81, 1.67]		
Geographic location						Syntax score (core	lab assessment)				
- North America	24.2% (89/381)	17.3% (61/371)	1.57 [1.09, 2.26]			- ≤22	17.2% (49/294)	16.7% (58/364)	0.99 [0.65, 1.51]		
- Europe	21.1% (111/534)	19.6% (102/541)	1.09 [0.81, 1.48]	<mark></mark>	0.82	- 23 - 32	23.7% (91/392)	20.7% (69/346)	1.22 [0.85, 1.74]		0.14
- Other	9.6% (3/33)	29.6% (13/45)	0.24 [0.06, 0.96]			- ≥33	25.0% (56/228)	20.2% (42/216)	1.36 [0.86, 2.15]		
			0.2		5				0.2	0.5 0.81 1.5 2	5
				Favors PCI Favors CAE	BG					Favors PCI Favors CAB	G
				Odds Ratio [95% C						Odds Ratio [95% C	


No significant interactions

EXCEL Analysis of 10 pre-specified subgroups All-cause Death, Stroke or MI at 5 Years




No significant interactions

EXCEL Analysis of 10 pre-specified subgroups All-cause Death, Stroke or MI at 5 Years



No significant interactions

EXCEL Analysis of 10 pre-specified subgroups All-cause Death, Stroke or MI at 5 Years



No significant interactions


EXCEL Analysis of 10 pre-specified subgroups All-cause Death, Stroke or MI at 5 Years

- ≥33		25.09	% (56/228)	20.2% (42/216)	1.36 [0.86, 2	2.15]				
- 23 - 32		23.79	% (91/392)	20.7% (69/346)	1.22 [0.85, 1	L.74]				0.14
- ≤22		17.29	% (49/294)	16.7% (58/364)	0.99 [0.65, 1	l. 51]				
Syntax sc	ore (core l	ab assess	<u>sment)</u>							
- Yes - No	29.0% (72/256) 19.4% (131/692)	25.5% (62/249) 16.9% (114/707)	1.24 [0.83, 1.86] 1.17 [0.89, 1.55]	0.81	<u>Left main bifurca</u> - Yes	ation or trifurcation sten 22.7% (171/771)	<u>osis ≥50% (core lab</u> 19.0% (136/741)			
<u>Diabetes mellitus,</u>			4 24 [0 02 4 06]			19.2% (31/162)	20.7% (37/182)	0.93 [0.54, 1.59]		
- Female	26.3% (58/226)	21.1% (42/215)	1.39 [0.88, 2.20]			25.0% (79/325)	17.8% (50/295)	0.94 [0.62, 1.40] 1.58 [1.06, 2.36]		0.29
<u>Sex</u> - Male	20.6% (145/722)	18.7% (134/742)	1.12 [0.86, 1.46]	0.42	<u>Non-left main di</u> - 0 - 1	seased coronary arteries 20.7% (33/163) 21.2% (60/292)	<u>(core lab assessme</u> 14.3% (23/167) 21.9% (61/292)	1.55 [0.86, 2.78]		
- <67 years	16.9% (80/482)	16.6% (78/485)	1.00 [0. 71, 1.40]		- <50%	31.5% (33/111)	24.2% (26/115)	1.35 [0.73, 2.49]		
<u>Age (median cutof</u> - ≥67 years	<u>f)</u> 27.2% (123/466)	21.8% (98/472)	1.39 [1.02, 1.89]	0.95	<u>Left ventricular e</u> - ≥50%	ejection fraction 20.6% (158/782)	18.7% (144/796)	1.14 [0.88, 1.46]		0.61
All patients	22.0% (203/948)	19.2% (176/957)	1.19 [0.95, 1.50]	⊢ ∎	All patients	22.0% (203/948)	19.2% (176/957)	1.19 [0.95, 1.50]		
				OR [95% CI] P _{int}	Subgroup	PCI N=948	CABG N=957	OR [95% CI]	OR [95% CI]	P _{int}


No significant interactions



Primary Endpoint Non-proportional Hazards




EXCEL Piecewise Hazards **All-cause Death, Stroke or Ml** Three distinct periods of varying relative risk




Restricted Mean Survival Time Analysis All-cause Death, Stroke or Ml

EXCEL



Restricted Mean Survival Time Analysis All-cause Death, Stroke or MI



EXCEL

At the end of the 5-year follow-up period, event-free survival time was 5.2 days (95% CI -46.1 to 56.5 days) longer after PCI compared with CABG



Outcomes at 30 Days

	PCI (n=948)	CABG (n=957)	HR [95%CI]	P-value
Death, stroke or MI	4.9%	7.9%	0.61 [0.42, 0.88]	0.008
- Death	1.0%	1.1%	0.90 [0.37, 2.22]	0.82
- Stroke	0.6%	1.3%	0.50 [0.19, 1.33]	0.15
- MI	3.9%	6.2%	0.63 [0.42, 0.95]	0.02
- Peri-procedural	3.6%	5.9%	0.61 [0.40, 0.93]	0.02
- Spontaneous	0.3%	0.3%	1.00 [0.20, 4.95]	1.00
- STEMI	0.7%	2.3%	0.32 [0.14, 0.74]	0.005
- Non-STEMI	3.2%	3.9%	0.82 [0.50, 1.32]	0.41
Death, stroke, MI or IDR	4.9%	8.4%	0.57 [0.40, 0.82]	0.002
- Ischemia-driven revasc (IDR)	0.6%	1.4%	0.46 [0.18, 1.21]	0.11
Stent thrombosis, def/prob	0.6%	0.0%	-	0.01
Graft occlusion, symptomatic	0.0%	1.2%	-	<0.001
Definite stent thrombosis or symptomatic graft occlusion	0.3%	1.2%	0.27 [0.08, 0.97]	0.03

Stone GW et al. N Engl J Med 2016;375:2223-35

EXCEL Major Adverse Events Within 30 Days

	PCI (n=948)	CABG (n=957)	RR [95%CI]	P-value
Peri-procedural MAE, any	12.4%	44.0%	0.28 [0.24, 0.34]	<0.001
- Death*	0.9%	1.0%	0.91 [0.39, 2.23]	0.83
- Stroke*	0.6%	1.3%	0.50 [0.19, 1.34]	0.16
- Myocardial infarction*	3.9%	6.2%	0.63 [0.42, 0.95]	0.02
- Ischemia-driven revascularization*	0.6%	1.4%	0.47 [0.18, 1.22]	0.11
- TIMI major/minor bleeding	3.7%	8.9%	0.42 [0.28, 0.61]	<0.001
- Transfusion ≥2 units	4.0%	17.0%	0.24 [0.17, 0.33]	<0.001
- Major arrhythmia**	2.1%	16.1%	0.13 [0.08, 0.21]	<0.001
- Surgery/radiologic procedure	1.3%	4.1%	0.31 [0.16, 0.59]	<0.001
- Renal failure [†]	0.6%	2.5%	0.25 [0.10, 0.61]	<0.001
- Sternal wound dehiscence	0.0%	2.0%	0.03 [0.00, 0.43]	<0.001
- Infection requiring antibiotics	2.5%	13.6%	0.18 [0.12, 0.28]	<0.001
- Prolonged intubation (>48 hours)	0.4%	2.9%	0.14 [0.05, 0.41]	<0.001
- Post-pericardiotomy syndrome	0.0%	0.4%	0.11 [0.01, 2.08]	0.12

*Adjudicated events; others are site-reported. **SVT requiring cardioversion, VT or VF requiring treatment, or bradyarrhythmia requiring temp or perm PM. [†]SCr increased by ≥0.5 mg/dL from baseline or need for dialysis.

Stone GW et al. N Engl J Med 2016;375:2223-35



	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]



	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]



	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]



	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]

EXCELAdjudicated Non-Cardiovascular Causes of Death

	PCI (N=948)	CABG (N=957)	Difference [95% CI]
Definite non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]
Pulmonary	1.0% (8)	0.6% (5)	0.4% [-0.5%, 1.2%]
Infection (includes sepsis)	1.6% (14)	0.8% (7)	0.8% [-0.2%, 1.8%]
Gastrointestinal	0.1% (1)	0.2% (2)	-0.1% [-0.5%, 0.3%]
Malignancy	3.4% (29)	2.7% (23)	0.7% [-1.0%, 2.3%]
Accident/trauma	0.3% (3)	0.2% (2)	0.1% [-0.4%, 0.6%]
Non-cardiovascular organ failure	0.2% (2)	0.0% (0)	0.2% [-, -]
Other non-cardiovascular cause	0.0% (0)	0.2% (2)	-0.2% [-, -]

Updated Meta-analysis of LM DES vs. CABG Trials 5 RCTs, 4,612 pts, mean 5.6-year FU Including long-term EXCEL, NOBLE and SYNTAX data All-cause Death

	PC		CAI	BG			
Study and Year	Events	Ν	Events	Ν	Weight (%)		Relative risk [95% CI]
Risk of death							
NOBLE – 5 year, 2019	54	592	50	592	22.4		1.08 [0.75, 1.56]
SYNTAX – 10 year, 2019	93	357	98	348	32.9		0.93 [0.73, 1.18]
EXCEL – 5 year, 2019	119	948	89	957	31.3	-	1.35 [1.04, 1.75]
PRECOMBAT – 5 year, 2015	17	300	23	300	11.4		0.74 [0.40, 1.36]
Boudriot – 1 year 2011	2	100	5	101	2.0		0.40 [0.08, 2.03]
REML model for all studies	s (Q=7. <u>28</u>	3, df= <u>4</u> ,	p for hete	rogene	eity=0.12; <mark> </mark> 2 =	= 42.9%) 🔶	1.03 [0.82, 1.30]
							P overall effect = 0.78
Moderate heterogeneity	/ due to	EXCE	L. If EXC	EL rer	moved: г		
RR 0.93, 95% CI	0.77-1.	13; P=	: 0.47; l ² :	= 0.0%	6 0.0	04 0.2 1	5 25
						etter < Relative risk	CARC bottor

Ahmad Y et al. EHJ 2020:on-line

Hear

Research Foundation




	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]



	PCI (N=948)	CABG (N=957)	Difference [95% CI]	Odds ratio [95% CI]
Death, stroke or MI	22.0% (203)	19.2% (176)	2.8% [-0.9%, 6.5%]	1.19 [0.95, 1.50]
Death, all-cause	13.0% (119)	9.9% (89)	3.1% [0.2%, 6.1%]	1.38 [1.03, 1.85]
- Cardiovascular	6.8% (61)	5.5% (49)	1.3% [-0.9%, 3.6%]	1.26 [0.85, 1.85]
- Definite cardiovascular	5.0% (45)	4.5% (40)	0.5% [-1.4%, 2.5%]	1.13 [0.73, 1.74]
- Undetermined cause	1.9% (16)	1.1% (9)	0.9% [-0.3%, 2.0%]	1.78 [0.78, 4.06]
- Non-cardiovascular	6.6% (58)	4.6% (40)	2.0% [-0.2%, 4.2%]	1.47 [0.97, 2.23]
Cerebrovascular events	3.3% (29)	5.2% (46)	-1.9% [-3.8%, 0.0%]	0.61 [0.38, 0.99]
- Stroke	2.9% (26)	3.7% (33)	-0.8% [-2.4%, 0.9%]	0.78 [0.46, 1.31]
- Transient ischemic attack	0.3% (3)	1.6% (14)	-1.3% [-2.2%, -0.4%]	0.21 [0.06, 0.74]
Myocardial infarction	10.6% (95)	9.1% (84)	1.4% [-1.3%, 4.2%]	1.14 [0.84, 1.55]
- Peri-procedural	3.9% (37)	6.1% (57)	-2.1% [-4.1%, -0.1%]	0.63 [0.41, 0.96]
- Non-peri-procedural	6.8% (59)	3.5% (31)	3.2% [1.2%, 5.3%]	1.96 [1.25, 3.06]
ID-revascularization	16.9% (150)	10.0% (88)	6.9% [3.7%, 10.0%]	1.84 [1.39, 2.44]

SF-12 Physical Summary Scale


EXCEL



Baron SJ et al. JACC 2017;70:3113-22



SAQ-Angina Frequency



Baron SJ et al. JACC 2017;70:3113-22

Left Main PCI vs. CABG Heart Team Discussions: Two very different procedures

PCI

Early advantages
Less invasive
Fewer peri-procedural complications (stroke, MI, Afib, bleeding, AKI, etc.)
Lower 30-day MACE
More rapid recovery with better early QoL and earlier angina relief



CABG

Late advantages • More durable • Fewer adverse events beyond 1 year – particularly MI and repeat revascularization procedures

PCI and CABG

No significant <u>major</u> differences in long-term survival, MACE (death, MI or stroke) or QoL



